多发性骨髓瘤药物市场：按药物、分布分类 - 全球预测 2023-2030

预计2023年全球多发性骨髓瘤药物市场将大幅成长至227亿美元，年复合成长率为8.02%，预计2030年将达到惊人的390.2亿美元。

FPNV定位矩阵

FPNV定位矩阵对于评估全球多发性骨髓瘤治疗市场至关重要。透过检查业务策略和产品满意度的关键指标，我们对供应商进行全面评估，使您能够根据您的特定需求做出明智的资讯。这种进阶分析将供应商分为四个像限，并取得了不同程度的成功：前沿 (F)、探路者 (P)、利基 (N) 和重要 (V)。

市占率分析

市场占有率分析可以深入了解供应商在特定市场领域的当前地位。比较供应商对总收入、基本客群和其他关键指标的贡献，可以帮助公司更好地了解他们在争夺市场份额时的表现以及面临的情况。该分析还揭示了特定行业的竞争程度、累积和合併的优势以及研究基准年的合併特征。

本报告提供了以下几点见解：

1. 市场渗透率：提供有关主要企业所服务的市场的全面资讯。

2. 市场开发：提供有关利润丰厚的新兴市场的详细资讯，并分析其在成熟市场的渗透率。

3. 市场多元化：提供有关新产品发布、未开发地区、最新发展和投资的详细资讯。

4.市场趋势：全面了解COVID-19、俄罗斯-乌克兰衝突和高通膨的累积影响。

5.竞争评估与资讯：对主要企业的市场占有率、策略、产品、认证、法规状况、专利状况、製造能力等进行综合评估。

6. 产品开发与创新：提供对未来技术、研发活动和突破性产品开发的见解。

本报告回答了以下问题：

1.多发性骨髓瘤治疗药物的全球市场规模与预测为何？

2.在预测期内，COVID-19对全球多发性骨髓瘤治疗药物市场的阻碍因素与影响有哪些？

3.在预测期内，全球多发性骨髓瘤治疗药物市场需要投资哪些产品/细分市场/应用/领域？

4.你们在全球多发性骨髓瘤药物市场的竞争策略是什么？

5.全球多发性骨髓瘤药物市场的技术趋势和法律规范是什么？

6.全球多发性骨髓瘤治疗药物市场主要厂商的市占率为何？

7. 哪些型态和策略性措施被认为适合进入多发性骨髓瘤药物全球市场？

目录

第1章前言

第2章调查方法

第3章执行摘要

第4章市场概况

第5章市场洞察

• 市场动态
  • 促进因素
    • 多发性骨髓瘤的适应症和盛行率不断增加
    • 有吸引力的报销制度支持已开发国家的治疗
    • 透过仿製药批准增加药物供应
  • 抑制因素
    • 严格的药品审批流程
  • 机会
    • 产品开发、药物临床临床实验和商业化之间的合作
    • 采用标靶治疗和皮质类固醇
  • 任务
    • 潜在的副作用
• 市场趋势
• COVID-19 的累积影响
• 俄罗斯-乌克兰衝突的累积影响
• 高通膨的累积效应
• 波特五力分析
• 价值炼和关键路径分析
• 法律规范
• 客户客製化

第6章多发性骨髓瘤治疗药物市场（依药物）

• 组蛋白去乙酰化酶抑制剂
• 免疫调节剂
• 单株抗体
• 蛋白酶体抑制剂

第7章多发性骨髓瘤治疗药物市场分布

• 医院药房
• 线上通路
• 零售药房

第8章美洲多发性骨髓瘤药物市场

• 阿根廷
• 巴西
• 加拿大
• 墨西哥
• 美国

第9章亚太地区多发性骨髓瘤药物市场

• 澳洲
• 中国
• 印度
• 印尼
• 日本
• 马来西亚
• 菲律宾
• 新加坡
• 韩国
• 台湾
• 泰国
• 越南

第10章欧洲、中东及非洲多发性骨髓瘤药物市场

• 丹麦
• 埃及
• 芬兰
• 法国
• 德国
• 以色列
• 义大利
• 荷兰
• 奈及利亚
• 挪威
• 波兰
• 卡达
• 俄罗斯
• 沙乌地阿拉伯
• 南非
• 西班牙
• 瑞典
• 瑞士
• 土耳其
• 阿拉伯聯合大公国
• 英国

第11章竞争形势

• FPNV定位矩阵
• 市占率分析：主要企业
• 竞争情境分析：主要企业

第12章上市公司名单

第13章附录

• 讨论指南
• 关于许可证和定价

The Global Multiple Myeloma Drug Market is forecasted to grow significantly, with a projected USD 22.70 billion in 2023 at a CAGR of 8.02% and expected to reach a staggering USD 39.02 billion by 2030.

The Cumulative Impact of COVID-19, the Russia-Ukraine Conflict, and High Inflation is expected to have significant long-term effects on the Global Multiple Myeloma Drug Market. The ongoing research considers the changes in consumer behavior, supply chain disruptions, and government interventions caused by the pandemic. Similarly, the report considers the ongoing political and economic uncertainty in Eastern Europe caused by the Russia-Ukraine Conflict and its potential implications for demand-supply balances, pressure on pricing variants, and import/export and trading. Additionally, the report addresses the impact of High Inflation on the global economy and details fiscal policies measuring and reducing its effects on demand, supply, cash flow, and currency exchange.

Market Segmentation & Coverage:

This research report categorizes the Global Multiple Myeloma Drug Market in order to forecast the revenues and analyze trends in each of following sub-markets:

Based on Drug, market is studied across Histone Deacetylase Inhibitors, Immunomodulating Agents, Monoclonal Antibodies, and Proteasome Inhibitors. The Proteasome Inhibitors is projected to witness significant market share during forecast period.

Based on Distribution, market is studied across Hospital Pharmacy, Online Channel, and Retail Pharmacy. The Hospital Pharmacy is projected to witness significant market share during forecast period.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom. The Americas commanded largest market share of 38.75% in 2022, followed by Europe, Middle East & Africa.

Market Statistics:

The report provides market sizing and forecasts across 7 major currencies - USD, EUR, JPY, GBP, AUD, CAD, and CHF; multiple currency support helps organization leaders to make well-informed decisions. In this report, 2018 to 2021 are considered as historical years, 2022 is base year, 2023 is estimated year, and years from 2024 to 2030 are considered as forecast period.

FPNV Positioning Matrix:

The FPNV Positioning Matrix is essential for assessing the Global Multiple Myeloma Drug Market. It provides a comprehensive evaluation of vendors by examining key metrics within Business Strategy and Product Satisfaction, allowing users to make informed decisions based on their specific needs. This advanced analysis then organizes these vendors into four distinct quadrants, which represent varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital(V).

Market Share Analysis:

The Market Share Analysis offers an insightful look at the current state of vendors in a particular market space. By comparing vendor contributions to overall revenue, customer base, and other key metrics, we can give companies a greater understanding of their performance and what they are up against when competing for market share. The analysis also sheds light on just how competitive any given sector is about accumulation, fragmentation dominance, and amalgamation traits over the base year period studied.

The report provides insights on the following pointers:

1. Market Penetration: Provides comprehensive information on the market offered by the key players

2. Market Development: Provides in-depth information about lucrative emerging markets and analyzes penetration across mature segments of the markets

3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments

4. Market Trends: Provides comprehensive understanding of the Cumulative Impact of COVID-19, the Russia-Ukraine Conflict, and the High Inflation

5. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players

6. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:

1. What is the market size and forecast of the Global Multiple Myeloma Drug Market?

2. What are the inhibiting factors and impact of COVID-19 shaping the Global Multiple Myeloma Drug Market during the forecast period?

3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Multiple Myeloma Drug Market?

4. What is the competitive strategic window for opportunities in the Global Multiple Myeloma Drug Market?

5. What are the technology trends and regulatory frameworks in the Global Multiple Myeloma Drug Market?

6. What is the market share of the leading vendors in the Global Multiple Myeloma Drug Market?

7. What modes and strategic moves are considered suitable for entering the Global Multiple Myeloma Drug Market?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Limitations
• 1.7. Assumptions
• 1.8. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

• 4.1. Introduction
• 4.2. Multiple Myeloma Drug Market, by Drug, 2022 vs 2030
• 4.3. Multiple Myeloma Drug Market, by Distribution, 2022 vs 2030
• 4.4. Multiple Myeloma Drug Market, by Region, 2022 vs 2030

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Increased indication and prevalence of Multiple Myeloma
    • 5.1.1.2. Attractive reimbursement policies supporting treatments in developed countries
    • 5.1.1.3. Increased drug availability along with approvals for generics
  • 5.1.2. Restraints
    • 5.1.2.1. Stringent drug approval process
  • 5.1.3. Opportunities
    • 5.1.3.1. Collaborating product development and drug trials and commercialization
    • 5.1.3.2. Targeted therapy and adoption of Corticosteroids
  • 5.1.4. Challenges
    • 5.1.4.1. Potential side effects
• 5.2. Market Trends
• 5.3. Cumulative Impact of COVID-19
• 5.4. Cumulative Impact of Russia-Ukraine Conflict
• 5.5. Cumulative Impact of High Inflation
• 5.6. Porter's Five Forces Analysis
  • 5.6.1. Threat of New Entrants
  • 5.6.2. Threat of Substitutes
  • 5.6.3. Bargaining Power of Customers
  • 5.6.4. Bargaining Power of Suppliers
  • 5.6.5. Industry Rivalry
• 5.7. Value Chain & Critical Path Analysis
• 5.8. Regulatory Framework
• 5.9. Client Customization

6. Multiple Myeloma Drug Market, by Drug

• 6.1. Introduction
• 6.2. Histone Deacetylase Inhibitors
• 6.3. Immunomodulating Agents
• 6.4. Monoclonal Antibodies
• 6.5. Proteasome Inhibitors

7. Multiple Myeloma Drug Market, by Distribution

• 7.1. Introduction
• 7.2. Hospital Pharmacy
• 7.3. Online Channel
• 7.4. Retail Pharmacy

8. Americas Multiple Myeloma Drug Market

• 8.1. Introduction
• 8.2. Argentina
• 8.3. Brazil
• 8.4. Canada
• 8.5. Mexico
• 8.6. United States

9. Asia-Pacific Multiple Myeloma Drug Market

• 9.1. Introduction
• 9.2. Australia
• 9.3. China
• 9.4. India
• 9.5. Indonesia
• 9.6. Japan
• 9.7. Malaysia
• 9.8. Philippines
• 9.9. Singapore
• 9.10. South Korea
• 9.11. Taiwan
• 9.12. Thailand
• 9.13. Vietnam

10. Europe, Middle East & Africa Multiple Myeloma Drug Market

• 10.1. Introduction
• 10.2. Denmark
• 10.3. Egypt
• 10.4. Finland
• 10.5. France
• 10.6. Germany
• 10.7. Israel
• 10.8. Italy
• 10.9. Netherlands
• 10.10. Nigeria
• 10.11. Norway
• 10.12. Poland
• 10.13. Qatar
• 10.14. Russia
• 10.15. Saudi Arabia
• 10.16. South Africa
• 10.17. Spain
• 10.18. Sweden
• 10.19. Switzerland
• 10.20. Turkey
• 10.21. United Arab Emirates
• 10.22. United Kingdom

11. Competitive Landscape

• 11.1. FPNV Positioning Matrix
• 11.2. Market Share Analysis, By Key Player
• 11.3. Competitive Scenario Analysis, By Key Player

12. List of Company Mentioned

13. Appendix

• 13.1. Discussion Guide
• 13.2. License & Pricing

LIST OF FIGURES

• FIGURE 1. MULTIPLE MYELOMA DRUG MARKET RESEARCH PROCESS
• FIGURE 2. MULTIPLE MYELOMA DRUG MARKET SIZE, 2022 VS 2030
• FIGURE 3. MULTIPLE MYELOMA DRUG MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG, 2022 VS 2030 (%)
• FIGURE 5. MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION, 2022 VS 2030 (%)
• FIGURE 6. MULTIPLE MYELOMA DRUG MARKET SIZE, BY REGION, 2022 VS 2030 (%)
• FIGURE 7. MULTIPLE MYELOMA DRUG MARKET DYNAMICS
• FIGURE 8. MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 9. MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 10. AMERICAS MULTIPLE MYELOMA DRUG MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 11. UNITED STATES MULTIPLE MYELOMA DRUG MARKET SIZE, BY STATE, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 12. ASIA-PACIFIC MULTIPLE MYELOMA DRUG MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 13. EUROPE, MIDDLE EAST & AFRICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 14. MULTIPLE MYELOMA DRUG MARKET, FPNV POSITIONING MATRIX, 2022
• FIGURE 15. MULTIPLE MYELOMA DRUG MARKET SHARE, BY KEY PLAYER, 2022

LIST OF TABLES

• TABLE 1. MULTIPLE MYELOMA DRUG MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2022
• TABLE 3. MULTIPLE MYELOMA DRUG MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 5. MULTIPLE MYELOMA DRUG MARKET SIZE, BY HISTONE DEACETYLASE INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 6. MULTIPLE MYELOMA DRUG MARKET SIZE, BY IMMUNOMODULATING AGENTS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 7. MULTIPLE MYELOMA DRUG MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 8. MULTIPLE MYELOMA DRUG MARKET SIZE, BY PROTEASOME INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 10. MULTIPLE MYELOMA DRUG MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. MULTIPLE MYELOMA DRUG MARKET SIZE, BY ONLINE CHANNEL, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. MULTIPLE MYELOMA DRUG MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. AMERICAS MULTIPLE MYELOMA DRUG MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 14. AMERICAS MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 15. AMERICAS MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 16. ARGENTINA MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 17. ARGENTINA MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 18. BRAZIL MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 19. BRAZIL MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 20. CANADA MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 21. CANADA MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 22. MEXICO MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 23. MEXICO MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 24. UNITED STATES MULTIPLE MYELOMA DRUG MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 25. UNITED STATES MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 26. UNITED STATES MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 27. ASIA-PACIFIC MULTIPLE MYELOMA DRUG MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 28. ASIA-PACIFIC MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 29. ASIA-PACIFIC MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 30. AUSTRALIA MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 31. AUSTRALIA MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 32. CHINA MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 33. CHINA MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 34. INDIA MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 35. INDIA MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 36. INDONESIA MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 37. INDONESIA MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 38. JAPAN MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 39. JAPAN MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 40. MALAYSIA MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 41. MALAYSIA MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 42. PHILIPPINES MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 43. PHILIPPINES MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 44. SINGAPORE MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 45. SINGAPORE MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 46. SOUTH KOREA MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 47. SOUTH KOREA MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 48. TAIWAN MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 49. TAIWAN MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 50. THAILAND MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 51. THAILAND MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 52. VIETNAM MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 53. VIETNAM MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 54. EUROPE, MIDDLE EAST & AFRICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 55. EUROPE, MIDDLE EAST & AFRICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 56. EUROPE, MIDDLE EAST & AFRICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 57. DENMARK MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 58. DENMARK MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 59. EGYPT MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 60. EGYPT MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 61. FINLAND MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 62. FINLAND MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 63. FRANCE MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 64. FRANCE MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 65. GERMANY MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 66. GERMANY MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 67. ISRAEL MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 68. ISRAEL MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 69. ITALY MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 70. ITALY MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 71. NETHERLANDS MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 72. NETHERLANDS MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 73. NIGERIA MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 74. NIGERIA MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 75. NORWAY MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 76. NORWAY MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 77. POLAND MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 78. POLAND MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 79. QATAR MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 80. QATAR MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 81. RUSSIA MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 82. RUSSIA MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 83. SAUDI ARABIA MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 84. SAUDI ARABIA MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 85. SOUTH AFRICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 86. SOUTH AFRICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 87. SPAIN MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 88. SPAIN MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 89. SWEDEN MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 90. SWEDEN MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 91. SWITZERLAND MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 92. SWITZERLAND MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 93. TURKEY MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 94. TURKEY MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 95. UNITED ARAB EMIRATES MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 96. UNITED ARAB EMIRATES MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 97. UNITED KINGDOM MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 98. UNITED KINGDOM MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 99. MULTIPLE MYELOMA DRUG MARKET, FPNV POSITIONING MATRIX, 2022
• TABLE 100. MULTIPLE MYELOMA DRUG MARKET SHARE, BY KEY PLAYER, 2022
• TABLE 101. MULTIPLE MYELOMA DRUG MARKET LICENSE & PRICING